BIOMAT Database Logo BIOMAT Database Logo

Clinical and bacteriological experience with cefodizime in acute purulent exacerbations of chronic bronchitis. 1992

B I Davies, and F P Maesen, and J J van den Bergh, and R J Costongs, and W H Geraedts, and H L Gubbelmans, and J C Meek
Dept. of Medical Microbiology, De Wever Ziekenhuis, Heerlen, The Netherlands.

1 or 2 g doses of cefodizime i.m. were studied in 287 patients admitted to hospital with acute purulent exacerbations of chronic bronchitis, mostly associated with Haemophilus influenzae, Streptococcus pneumoniae or Moraxella catarrhalis. Pharmacokinetic studies in serum and sputum on the first treatment day yielded mean peak serum concentrations of 50 to 100 mg/l, with corresponding sputum concentrations of 1.4 and 2.7 mg/l, after the two respective doses. No great differences were found between the clinical and microbiological results in the various dosage groups, and no corresponding improvement was noted with the highest dosages studied. In general, infection was eliminated in 90 to 95% of patients at the end of treatment, and in approximately 70 to 80% after a follow-up week. Some infections associated with beta-lactamase producing M. catarrhalis persisted or relapsed after treatment. Unwanted drug effects were recorded in five patients, leading to discontinuation in two. It is concluded that a single daily intramuscular dose of 1 g cefodizime for seven days produces satisfactory results in most patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001991 Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI. Bronchitides
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D013183 Sputum Material coughed up from the lungs and expectorated via the mouth. It contains MUCUS, cellular debris, and microorganisms. It may also contain blood or pus. Sputum, Induced,Induced Sputum,Induced Sputums,Sputums,Sputums, Induced

Related Publications

B I Davies, and F P Maesen, and J J van den Bergh, and R J Costongs, and W H Geraedts, and H L Gubbelmans, and J C Meek
Antibiotic regimens in severe and acute purulent exacerbations of chronic bronchitis.
June 1968, British medical journal,
B I Davies, and F P Maesen, and J J van den Bergh, and R J Costongs, and W H Geraedts, and H L Gubbelmans, and J C Meek
Amoxycillin and co-trimoxazole in acute purulent exacerbations of chronic bronchitis.
January 1977, Chemotherapy,
B I Davies, and F P Maesen, and J J van den Bergh, and R J Costongs, and W H Geraedts, and H L Gubbelmans, and J C Meek
Amoxycillin and co-trimoxazole in acute purulent exacerbations of chronic bronchitis.
January 1977, Chemotherapy,
B I Davies, and F P Maesen, and J J van den Bergh, and R J Costongs, and W H Geraedts, and H L Gubbelmans, and J C Meek
The tetracyclines in purulent exacerbations of chronic bronchitis.
May 1982, The Journal of antimicrobial chemotherapy,
B I Davies, and F P Maesen, and J J van den Bergh, and R J Costongs, and W H Geraedts, and H L Gubbelmans, and J C Meek
Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil.
May 2006, Antimicrobial agents and chemotherapy,
B I Davies, and F P Maesen, and J J van den Bergh, and R J Costongs, and W H Geraedts, and H L Gubbelmans, and J C Meek
Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis.
November 1992, The Journal of hospital infection,
B I Davies, and F P Maesen, and J J van den Bergh, and R J Costongs, and W H Geraedts, and H L Gubbelmans, and J C Meek
Co-trimoxazole in prevention of purulent exacerbations of chronic bronchitis.
April 1973, The Practitioner,
B I Davies, and F P Maesen, and J J van den Bergh, and R J Costongs, and W H Geraedts, and H L Gubbelmans, and J C Meek
Cephalexin in the prevention of purulent exacerbations of chronic bronchitis.
May 1972, The British journal of clinical practice,
B I Davies, and F P Maesen, and J J van den Bergh, and R J Costongs, and W H Geraedts, and H L Gubbelmans, and J C Meek
Acute exacerbations in chronic bronchitis.
December 1966, Physiotherapy,
B I Davies, and F P Maesen, and J J van den Bergh, and R J Costongs, and W H Geraedts, and H L Gubbelmans, and J C Meek
Cephazolin in severe purulent exacerbations of chronic bronchitis. Preliminary study.
January 1977, Chemotherapy,
Copied contents to your clipboard!